On February 11, 2011, Aptalis completed the acquisition of Eurand N.V., a global specialty pharmaceutical company with operating units in the United States and Europe. The new company began operations on February 14, 2011, under the name Aptalis.
To support our new operating model and business moving forward, nine executive positions reporting to Frank Verwiel, M.D. President and Chief Executive Officer were announced in March. The newly-named leaders who comprise our new Management Team (MT) for the combined organization are below.